

ONTOZRY[®] ▼
cenobamate

Managing drug–drug interactions with **ONTOZRY**[®]

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Adverse events and product complaints should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard for the UK or www.hpra.ie for Ireland. Adverse events and product complaints should also be reported to Angelini Pharma on (UK) +44 2034889643, (ROI) +353 1 584 4671 or UKIReporting@angelinipharma.com

Indication for United Kingdom: ONTOZRY[®] is indicated for the adjunctive treatment of focal-onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite treatment with at least 2 anti-epileptic medicinal products.¹

Indication for Republic of Ireland: ONTOZRY[®] is indicated for the adjunctive treatment of focal-onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least 2 anti-epileptic medicinal products.¹

Prescribing information and adverse event reporting information can be found by scanning the QR code or [click here](#) if you are viewing on a digital device.



 **Angelini**
Pharma

This material has been developed and funded by Angelini Pharma for UK and Irish healthcare professionals only and is not intended for patient use. Prescribing information can be found above and on the back page. MAT-UKI-0186-P | May 2025

Drug Interaction Overview

Concomitant ASMs		Adding ONTOZRY® may require the following dose adjustments: ¹
Lamotrigine	↑	Increase dose of ONTOZRY® depending on individual response
Carbamazepine		None required
Lacosamide		
Levetiracetam		
Oxcarbazepine		
Valproic acid ▼		
Clobazam	↓	Decrease dose of clobazam
Phenobarbital	↓	Decrease dose of phenobarbital depending on individual response (monitor phenobarbital during ONTOZRY® titration)
Phenytoin	↓	Decrease dose of phenytoin depending on individual response (monitor phenytoin during ONTOZRY® titration)

Please see the Summary of Product Characteristics for further information about ONTOZRY® interaction with other medicinal products.

ASM = anti-seizure medication.

Drug Interaction Overview

Interactions with contraceptives and enzyme substrates

Adding ONTOZRY® may require the following dose adjustments:!

Oral contraceptives

Women of reproductive potential concomitantly using oral contraceptives should practise **additional or alternative non-hormonal measures of birth control** during treatment with ONTOZRY® and until 4 weeks after treatment discontinuation

CYP3A4 substrates (e.g. midazolam)



Increase dose of medicines metabolised by CYP3A4

CYP2B6 substrates (e.g. bupropion)



Increase dose of medicines metabolised by CYP2B6

CYP2C19 substrates (e.g. omeprazole)



Decrease dose of medicines metabolised by CYP2C19

Please see the Summary of Product Characteristics for further information about ONTOZRY®.

CYP3A4 = cytochrome P450 family 3 subfamily A member 4;
CYP2B6 = cytochrome P450 family 2 subfamily B member 6;
CYP2C19 = cytochrome P450 family 2 subfamily C member 19.

Reference

1. ONTOZRY® Summary of Product Characteristics. United Kingdom and European Union.



If you would like to know more about ONTOZRY®, please scan the QR code or visit www.harmoniamentis.co.uk/uk-hcp/